Co-Diagnostics, Inc. CODX
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Co-Diagnostics, Inc. is a molecular diagnostics company focused on the development, manufacture, and commercialization of PCR-based diagnostic tests and related technologies. The company operates primarily in the in vitro diagnostics and life sciences industries, with an emphasis on infectious disease detection, genetic testing applications, and molecular laboratory solutions. Its core business centers on the design and sale of diagnostic reagents, testing platforms, and associated laboratory products used by hospitals, laboratories, public health agencies, and research institutions. Revenue has historically been driven by sales of COVID-19 diagnostic tests, molecular testing reagents, and related laboratory consumables, although the company has continued expanding into broader infectious disease and multiplex testing applications.
Co-Diagnostics is known for its proprietary CoPrimer technology platform, which is designed to improve PCR assay specificity and multiplexing capability while reducing the likelihood of nonspecific amplification. The company was founded in 2013 and is headquartered in Salt Lake City, Utah. During the COVID-19 pandemic, Co-Diagnostics experienced rapid global expansion due to demand for SARS-CoV-2 PCR tests authorized in multiple international markets. Since then, the company has focused on diversifying its product portfolio beyond pandemic-related testing into respiratory panels, vector-borne diseases, and point-of-care molecular diagnostics.
Business Operations
The company primarily operates through its molecular diagnostics business, including the development and commercialization of PCR-based assays and diagnostic instruments. Its principal products include infectious disease detection kits, multiplex PCR panels, and testing systems utilizing the company’s proprietary CoPrimer technology. Co-Diagnostics also develops integrated testing platforms such as the Co-Dx PCR Pro instrument and associated consumables designed for decentralized and near-patient testing environments. Revenue is generated through product sales, reagent kits, laboratory supplies, and international distribution agreements.
Co-Diagnostics maintains both domestic and international operations, with commercial activity extending across North America, Europe, Africa, Asia, and Latin America through distributors and strategic laboratory partnerships. The company has operated through subsidiaries including Co-Diagnostics Logistics LLC and has collaborated with regional distributors and laboratory networks to expand testing access globally. Its operational strategy emphasizes scalable assay manufacturing, intellectual property development, and deployment of molecular testing technologies in emerging and underserved healthcare markets.
Strategic Position & Investments
Co-Diagnostics has positioned itself as a specialized molecular diagnostics developer focused on cost-efficient, highly multiplexed PCR technologies. The company’s strategic direction includes expanding its infectious disease testing menu, increasing adoption of proprietary testing platforms, and pursuing opportunities in decentralized molecular diagnostics. Management has also emphasized broadening the utility of its technology into areas such as respiratory disease panels, tuberculosis, mosquito-borne illnesses, and agricultural or veterinary testing applications.
The company has invested in automation, assay development, and instrument commercialization to reduce dependence on pandemic-related revenues. Recent strategic initiatives have included development of portable and point-of-care testing systems, expansion of manufacturing capabilities, and continued intellectual property protection surrounding the CoPrimer platform. Public filings and investor disclosures also indicate ongoing investment in research and development intended to support multiplex diagnostics and future assay menu expansion. While the company has explored international partnerships and commercialization arrangements, publicly available information does not confirm major transformative acquisitions comparable to larger diagnostics peers.
Geographic Footprint
Co-Diagnostics is headquartered in Salt Lake City, Utah, and conducts business globally through a network of distributors, laboratories, and commercial partners. The company achieved broad international exposure during the COVID-19 pandemic, with testing products distributed across regions including Africa, Europe, Asia-Pacific, Latin America, and the Middle East. International markets have represented a meaningful portion of historical revenues, particularly through government and institutional procurement programs.
The company’s operational influence is strongest in regions seeking scalable and comparatively lower-cost molecular testing solutions. Co-Diagnostics has publicly disclosed commercial relationships and distribution activity in countries across Sub-Saharan Africa, where molecular testing infrastructure development has been a strategic focus. Its global footprint remains dependent on regulatory approvals, distributor relationships, and public health procurement cycles within international diagnostics markets.
Leadership & Governance
Co-Diagnostics was co-founded by Dwight Egan, who has played a central role in shaping the company’s technology and commercialization strategy. Leadership has emphasized innovation in molecular diagnostics, expansion of proprietary PCR technologies, and development of scalable testing systems designed for both centralized laboratories and decentralized healthcare environments. The company operates under a publicly traded corporate governance structure and files regular disclosures with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K and quarterly reports on Form 10-Q.
Key executives and leadership figures include:
- Dwight Egan – Chief Executive Officer
- Brian Brown – Chief Financial Officer
- Logan Green – Chief Operating Officer
- Robert L. Bream Jr. – Chairman of the Board
Public company disclosures indicate that management’s strategic vision is centered on expanding the company’s proprietary molecular testing ecosystem, increasing assay menu breadth, and pursuing sustainable growth beyond COVID-19-related demand cycles.